Decreased levels of SOCS2 are also observed in primary human AMLs and AML cell lines carrying RAS mutations, suggesting that targeting this Ras/Socs2/Jak2/Stat5 signaling axis may have therapeutic implications in AML. The gene discussed is SOCS2; the disease is acute myeloid leukemia.